Mutations Provide Potential, but Environment Determines Expression
Insights from Autopsy Pathology in Prostate Cancer
Autopsy studies of prostate tissue have revealed one of the most striking paradoxes in oncology: microscopic prostate cancer is extremely common, yet only a small minority of these tumours ever progress to clinically significant disease. Modern molecular analysis has further shown that many latent tumours contain genetic alterations classically associated with malignant progression. These observations challenge mutation-centred models of cancer and suggest that genetic alterations alone are insufficient to determine tumour behaviour. Instead, tumour fate appears to depend on ecological interactions between cancer cells and their surrounding microenvironment. This paper summarises the key pathological findings from autopsy studies and explores their implications for understanding prostate cancer progression.
01Introduction
For decades, cancer biology has largely been interpreted through the framework of genetic mutation accumulation. According to this model, cancers develop and progress as successive mutations provide cells with increasing growth advantages. However, autopsy studies of the prostate have revealed patterns that are difficult to reconcile with a purely mutation-driven explanation.
Microscopic prostate tumours are remarkably common in men who die from unrelated causes. Yet despite this high prevalence, only a small proportion of men experience clinically significant prostate cancer during their lifetimes. This discrepancy suggests that additional biological mechanisms determine whether a tumour remains dormant or progresses, and that the microenvironment, rather than the genome alone, may be the decisive variable.
02The Autopsy Discovery of Latent Prostate Cancer
Pathological examinations of prostates from men who died of non-prostate-related causes have consistently demonstrated a high prevalence of microscopic carcinoma. Early studies conducted in the mid-20th century, beginning with Franks' foundational 1954 survey, identified latent prostate tumours in a substantial proportion of adult men across all demographics studied.
Subsequent autopsy investigations confirmed that prevalence rises sharply with age. Studies have found histologically identifiable prostate cancer in 30–40% of men in their fifties, increasing to more than 60–70% in men over 80. A systematic review pooling data from 29 separate autopsy studies conducted between 1948 and 2013 confirmed this age-prevalence curve, reporting estimated mean prevalence rising from 5% in men under 30 to 59% in men over 79, a finding consistent across geographically and ethnically diverse populations.
The magnitude of the gap between histological prevalence and clinical incidence has been quantified at national scale. Analysis of more than 1.48 million autopsies registered in the Japanese APAC-J database between 1958 and 2023 found latent prostate cancer 6.9-fold more frequent than clinical incidence in men aged 75–79, a disparity that persisted across six decades of follow-up.
Importantly, the individuals in these studies did not die from prostate cancer, nor had many experienced symptoms related to the disease. These findings establish that microscopic prostate cancer is often a silent and biologically contained condition.
While latent tumours are common to the point of near-universality in older men, clinically dangerous prostate cancer remains comparatively rare. Something is restraining these tumours, and that something is not the genome.
03The Dormancy Phenomenon
The existence of widespread microscopic tumours that never progress suggests the presence of a state commonly described as tumour dormancy. In this condition, tumour cells persist but remain constrained by regulatory forces within the surrounding tissue environment.
Crucially, this is not passive neglect. The host tissue is actively suppressing expansion through immune surveillance, stromal signalling, and architectural constraint, a condition of enforced containment rather than biological indifference. Dormant tumours may exist in a dynamic balance between cell proliferation and cell death, while interactions with immune cells, stromal structures, and nutrient availability limit their net expansion.
This distinction matters for clinical interpretation: if dormancy is actively maintained rather than passively permitted, then interventions that disrupt tissue homeostasis, whether through systemic stress, hormonal perturbation, or procedural disruption, carry the theoretical risk of releasing previously contained cellular populations.
For many individuals, this balance may persist for decades without producing clinically detectable disease.
04Genetic Features of Latent Tumours
Advances in molecular pathology have allowed researchers to examine the genetic composition of microscopic prostate cancers discovered during autopsies. Surprisingly, many of these latent tumours contain genetic alterations that are also observed in clinically significant prostate cancer.
These alterations include well-recognised oncogenic events, including PTEN loss and TMPRSS2-ERG gene fusions, found in a meaningful proportion of histologically low-grade, asymptomatic tumours. The presence of such mutations demonstrates that latent tumours can possess molecular characteristics commonly associated with malignant potential.
However, despite harbouring these genetic features, many of these tumours remain microscopic and asymptomatic throughout the individual's lifetime. The mutations are present; the progression is not. This is the central observation that the mutation-accumulation model cannot adequately explain.
05The Mutation–Progression Paradox
The discovery that latent tumours may carry canonical oncogenic alterations challenges the assumption that mutations alone determine cancer behaviour. If aggressive genetic features were sufficient to drive disease progression, a far greater proportion of microscopic tumours would be expected to develop into clinically significant cancers. The observed rates of progression make clear that they are not.
Instead, autopsy pathology suggests that mutations create the potential for malignancy, but environmental conditions determine whether that potential is expressed.
Genetic mutations establish capabilities. Environmental and ecological factors determine whether those capabilities are activated.
This reframing has significant implications. It suggests that a tumour's genome is best understood as a set of conditional possibilities rather than a predetermined trajectory, and that the tissue ecology surrounding the tumour is a legitimate and primary target of biological interest.
06The Role of the Tumour Microenvironment
Increasing evidence suggests that the surrounding tissue environment plays a critical role in regulating tumour behaviour. The prostate tumour microenvironment includes stromal fibroblasts, immune cells, extracellular matrix structures, vascular supply, and metabolic gradients.
Together, these components create a regulatory scaffold that can restrain or permit tumour expansion. When these regulatory mechanisms remain intact, small tumour populations may remain contained. When they are disrupted, by inflammation, metabolic dysregulation, immune senescence, or other systemic stressors, previously dormant tumour cells may gain the opportunity to proliferate and evolve.
The tumour microenvironment thus functions as a biological governor: it does not determine which mutations are present, but it determines what those mutations are permitted to do.
07Ecological Containment of Microscopic Tumours
The autopsy findings support an ecological interpretation of prostate cancer biology. Many microscopic tumours exist as small cellular populations occupying constrained niches within normal tissue architecture. They persist but remain limited by environmental pressures: nutrient availability, immune surveillance, structural tissue organisation, and signalling from adjacent normal cells.
Cross-sectional autopsy studies comparing geographically distinct populations have provided powerful evidence for the terrain hypothesis. When prostates from Caucasian men in the United Kingdom and Japanese men in Tokyo were examined using identical protocols, the prevalence and biological features of latent prostate cancer were found to be virtually identical, despite dramatically different rates of clinical prostate cancer between the two populations. This finding suggests that the initiating cellular events occur at similar rates across populations; it is the systemic, metabolic, and environmental terrain that determines whether those latent clones progress to clinically significant disease.
In ecological terms, microscopic tumours resemble small populations of organisms in a stable ecosystem: present, metabolically active, but ecologically bounded. Just as a small biological population in an intact ecosystem rarely outcompetes established neighbours without environmental disruption, a microscopic tumour cluster may require ecological destabilisation before clonal expansion becomes possible.
Progression is not simply a genetic inevitability. It is an ecological event, one that requires not just a capable cell population, but a permissive or disrupted environment in which that population can expand.
08Implications for Understanding Prostate Cancer
The pathological evidence from autopsy studies suggests that prostate cancer progression cannot be explained solely by genetic mutation accumulation. Tumour behaviour depends on the interaction between genetic potential and environmental context, and the evidence indicates that the environment often has the stronger hand.
This reframes prostate cancer not simply as a genetic disease but as a dynamic biological system in which ecological conditions shape evolutionary outcomes. A tumour with aggressive mutational potential in a well-regulated microenvironment may remain clinically silent indefinitely. The same tumour population in a disrupted or permissive environment may progress.
For patients and clinicians alike, this perspective raises an important question: rather than asking only what mutations are present, should we also be asking what conditions govern whether those mutations find expression?
Autopsy pathology has established that microscopic prostate cancer is far more common than clinically significant disease, and that many latent tumours possess genetic alterations classically associated with malignancy. Taken together, these observations challenge purely mutation-centred explanations of cancer progression.
They support a broader and more ecologically grounded interpretation: mutations provide the potential for malignant behaviour, but environmental and microenvironmental conditions determine whether that potential is expressed. The genome sets the range of possibilities; the tissue ecology determines which possibility is realised.
Understanding prostate cancer through this ecological lens may provide valuable insights into tumour dormancy, progression risk, and the biological logic of long-term disease stability, and may ultimately inform approaches to care that work with the body's existing containment mechanisms rather than against them.
- Pre-diseaseRead phase →
- IndolentRead phase →